In the interim analysis at 2 years of 180 infants in the RAINBOW trial,13 as among 109 children at 2.5 years in the BEAT-ROP trial,14 there was significant reduction of high myopia following anti-VEGF treatment compared to laser, but no visual acuity data have been published following a trial of anti-VEGF therapy for ROP. This evidence concerns the gene VEGFA and myopia.